NCT04727086View on ClinicalTrials.gov

Role of BP1.3656 on Alcohol Responses

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Alcohol Use Disorder
Interventions
DRUG

BP1.3656

BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.

DRUG

Placebo

Administered once daily in tablet form.

Trial Locations (1)

M5S 2S1

Center for Addiction and Mental Health, Toronto

All Listed Sponsors
lead

Centre for Addiction and Mental Health

OTHER

NCT04727086 - Role of BP1.3656 on Alcohol Responses | Biotech Hunter | Biotech Hunter